Agios Pharma (AGIO) Tops Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- Wall St futures inch higher as chips extend gains
- Oil falls as investors await clarity after Iran-Israel halt attacks
- Tech stocks gain as Trump mulls government stake in AI companies
- Morgan Stanley’s Wilson calls Friday U.S. selloff a "healthy reset"
- Hedge funds loaded up on equities ahead of sharp Friday drop
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Salesforce to acquire metering platform M3TER for consumption billing
- Quantum Space to go public via $1.2B SPAC merger
- SpaceX sets $135 price for blockbuster IPO, upending Wall Street convention
Agios Reports Business Highlights and First Quarter 2019 Financial Results
May 2, 2019 7:00 AM EDTCommercial Organization Launch Ready Ahead of June 21, 2019 PDUFA Action Date for Single Agent TIBSOVO® for IDH1m Newly Diagnosed AML
Updated Data from Phase 1 Studies of TIBSOVO® in Newly Diagnosed AML and First Data from Perioperative Study of TIBSOVO® and Vorasidenib Accepted for Presentation at ASCO Â
Broad Clinical Development Plan for Mitapivat Progressing with Pyruvate Kinase Deficiency Pivotal Studies Enrolling, First Patient Dosed in Phase 2 Thalassemia Study and NIH-Sponsored Sickle Cell Study to Initiate in 2019
$9.1M First Quarter Net Revenue for TIBSOVO®; March 31, 2019... More
